{
    "2018-08-12": [
        [
            {
                "time": "2018-08-12",
                "original_text": "【申万宏源医药闫天一】20180812 周观点：企稳，市场情绪自我修复",
                "features": {
                    "keywords": [
                        "申万宏源",
                        "医药",
                        "企稳",
                        "市场情绪",
                        "自我修复"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-12",
                "original_text": "恒瑞医药：公司产品拟纳入优先审评程序",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "优先审评",
                        "产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-12",
                "original_text": "医疗保健：创新药进入兑现期 荐8股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "创新药",
                        "兑现期"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-12",
                "original_text": "[买入-A评级] 恒瑞医药(600276)中报点评：中报业绩稳健增长 多款重磅新药进入收获期",
                "features": {
                    "keywords": [
                        "买入",
                        "A评级",
                        "恒瑞医药",
                        "中报",
                        "业绩稳健增长",
                        "重磅新药",
                        "收获期"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}